symbol,statement_type,period_end,line_item,value
BALPHARMA.NS,income,2025-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Tax Rate For Calcs,0.3
BALPHARMA.NS,income,2025-03-31 00:00:00,Normalized EBITDA,317628000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Total Unusual Items,0.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Total Unusual Items Excluding Goodwill,0.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,72154000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Reconciled Depreciation,97709000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Reconciled Cost Of Revenue,1578934000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,EBITDA,317628000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,EBIT,219919000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Net Interest Income,-168544000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Interest Expense,168544000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Interest Income,
BALPHARMA.NS,income,2025-03-31 00:00:00,Normalized Income,72154000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,72154000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Total Expenses,2832943000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Rent Expense Supplemental,
BALPHARMA.NS,income,2025-03-31 00:00:00,Diluted Average Shares,15823246.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Basic Average Shares,15823246.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Diluted EPS,4.56
BALPHARMA.NS,income,2025-03-31 00:00:00,Basic EPS,4.56
BALPHARMA.NS,income,2025-03-31 00:00:00,Diluted NI Availto Com Stockholders,72154000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Net Income Common Stockholders,72154000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Net Income,72154000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Minority Interests,-213000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Net Income Including Noncontrolling Interests,72367000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Net Income Continuous Operations,72367000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Tax Provision,-20992000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Pretax Income,51375000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Other Non Operating Income Expenses,22029000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Special Income Charges,0.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Other Special Charges,
BALPHARMA.NS,income,2025-03-31 00:00:00,Write Off,
BALPHARMA.NS,income,2025-03-31 00:00:00,Net Non Operating Interest Income Expense,-168544000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Total Other Finance Cost,
BALPHARMA.NS,income,2025-03-31 00:00:00,Interest Expense Non Operating,168544000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Interest Income Non Operating,
BALPHARMA.NS,income,2025-03-31 00:00:00,Operating Income,197890000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Operating Expense,1254009000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Other Operating Expenses,532295000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Depreciation And Amortization In Income Statement,97709000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Amortization,
BALPHARMA.NS,income,2025-03-31 00:00:00,Depreciation Income Statement,97709000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Research And Development,
BALPHARMA.NS,income,2025-03-31 00:00:00,Selling General And Administration,
BALPHARMA.NS,income,2025-03-31 00:00:00,Selling And Marketing Expense,
BALPHARMA.NS,income,2025-03-31 00:00:00,General And Administrative Expense,
BALPHARMA.NS,income,2025-03-31 00:00:00,Rent And Landing Fees,
BALPHARMA.NS,income,2025-03-31 00:00:00,Gross Profit,1451899000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Cost Of Revenue,1578934000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Total Revenue,3030833000.0
BALPHARMA.NS,income,2025-03-31 00:00:00,Operating Revenue,3030833000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Tax Rate For Calcs,0.177023
BALPHARMA.NS,income,2024-03-31 00:00:00,Normalized EBITDA,336008000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Total Unusual Items,0.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Total Unusual Items Excluding Goodwill,0.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,73922000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Reconciled Depreciation,100711000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Reconciled Cost Of Revenue,1917519000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,EBITDA,336008000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,EBIT,235297000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Net Interest Income,-144823000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Interest Expense,144823000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Interest Income,5596000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Normalized Income,73922000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,73922000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Total Expenses,3185383000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Rent Expense Supplemental,10492000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Diluted Average Shares,14963968.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Basic Average Shares,14963968.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Diluted EPS,4.94
BALPHARMA.NS,income,2024-03-31 00:00:00,Basic EPS,4.94
BALPHARMA.NS,income,2024-03-31 00:00:00,Diluted NI Availto Com Stockholders,73922000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Net Income Common Stockholders,73922000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Net Income,73922000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Minority Interests,-535000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Net Income Including Noncontrolling Interests,74458000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Net Income Continuous Operations,74458000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Tax Provision,16016000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Pretax Income,90474000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Other Non Operating Income Expenses,28482000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Special Income Charges,0.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Other Special Charges,-827000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Write Off,
BALPHARMA.NS,income,2024-03-31 00:00:00,Net Non Operating Interest Income Expense,-144823000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Total Other Finance Cost,25364000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Interest Expense Non Operating,144823000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Interest Income Non Operating,5596000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Operating Income,206813000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Operating Expense,1267864000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Other Operating Expenses,562391000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Depreciation And Amortization In Income Statement,100711000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Amortization,39204000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Depreciation Income Statement,100711000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Research And Development,
BALPHARMA.NS,income,2024-03-31 00:00:00,Selling General And Administration,221689000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Selling And Marketing Expense,179009000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,General And Administrative Expense,42680000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Rent And Landing Fees,10492000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Gross Profit,1474677000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Cost Of Revenue,1917519000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Total Revenue,3392196000.0
BALPHARMA.NS,income,2024-03-31 00:00:00,Operating Revenue,3392196000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Tax Effect Of Unusual Items,315770.4
BALPHARMA.NS,income,2023-03-31 00:00:00,Tax Rate For Calcs,0.2376
BALPHARMA.NS,income,2023-03-31 00:00:00,Normalized EBITDA,242399000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Total Unusual Items,1329000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Total Unusual Items Excluding Goodwill,1329000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,25717000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Reconciled Depreciation,91283000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Reconciled Cost Of Revenue,1762439000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,EBITDA,243728000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,EBIT,152445000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Net Interest Income,-120825000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Interest Expense,104960000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Interest Income,2313000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Normalized Income,24703770.4
BALPHARMA.NS,income,2023-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,25717000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Total Expenses,2841623000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Rent Expense Supplemental,7636000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Diluted Average Shares,15690000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Basic Average Shares,15690000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Diluted EPS,1.67
BALPHARMA.NS,income,2023-03-31 00:00:00,Basic EPS,1.67
BALPHARMA.NS,income,2023-03-31 00:00:00,Diluted NI Availto Com Stockholders,25717000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Net Income Common Stockholders,25717000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Net Income,25717000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Minority Interests,-475000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Net Income Including Noncontrolling Interests,26193000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Net Income Continuous Operations,26193000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Tax Provision,21292000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Pretax Income,47485000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Other Non Operating Income Expenses,5764000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Special Income Charges,1329000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Other Special Charges,-1329000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Write Off,0.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Net Non Operating Interest Income Expense,-120825000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Total Other Finance Cost,18178000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Interest Expense Non Operating,104960000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Interest Income Non Operating,2313000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Operating Income,175450000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Operating Expense,1079184000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Other Operating Expenses,265895000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Depreciation And Amortization In Income Statement,91282000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Amortization,19677000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Depreciation Income Statement,71605000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Research And Development,0.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Selling General And Administration,181977000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Selling And Marketing Expense,147741000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,General And Administrative Expense,34236000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Rent And Landing Fees,7636000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Gross Profit,1254634000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Cost Of Revenue,1762439000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Total Revenue,3017073000.0
BALPHARMA.NS,income,2023-03-31 00:00:00,Operating Revenue,3017073000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Tax Effect Of Unusual Items,6468235.2
BALPHARMA.NS,income,2022-03-31 00:00:00,Tax Rate For Calcs,0.2884
BALPHARMA.NS,income,2022-03-31 00:00:00,Normalized EBITDA,248548000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Total Unusual Items,22428000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Total Unusual Items Excluding Goodwill,22428000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,56115000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Reconciled Depreciation,90401000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Reconciled Cost Of Revenue,1678183000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,EBITDA,270976000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,EBIT,180575000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Net Interest Income,-105387000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Interest Expense,88752000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Interest Income,3701000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Normalized Income,40155235.2
BALPHARMA.NS,income,2022-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,56115000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Total Expenses,2646392000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Rent Expense Supplemental,5644000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Diluted Average Shares,14822000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Basic Average Shares,14822000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Diluted EPS,3.785926
BALPHARMA.NS,income,2022-03-31 00:00:00,Basic EPS,3.785926
BALPHARMA.NS,income,2022-03-31 00:00:00,Diluted NI Availto Com Stockholders,56115000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Net Income Common Stockholders,56115000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Net Income,56115000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Minority Interests,-934000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Net Income Including Noncontrolling Interests,57048000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Net Income Continuous Operations,57048000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Tax Provision,34775000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Pretax Income,91823000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Other Non Operating Income Expenses,17338000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Special Income Charges,22428000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Other Special Charges,-22428000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Write Off,0.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Net Non Operating Interest Income Expense,-105387000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Total Other Finance Cost,20336000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Interest Expense Non Operating,88752000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Interest Income Non Operating,3701000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Operating Income,150597000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Operating Expense,968209000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Other Operating Expenses,230550000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Depreciation And Amortization In Income Statement,90401000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Amortization,14684000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Depreciation Income Statement,75717000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Research And Development,0.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Selling General And Administration,175223000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Selling And Marketing Expense,148169000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,General And Administrative Expense,27054000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Rent And Landing Fees,5644000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Gross Profit,1118806000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Cost Of Revenue,1678183000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Total Revenue,2796989000.0
BALPHARMA.NS,income,2022-03-31 00:00:00,Operating Revenue,2796989000.0
BALPHARMA.NS,income,2021-03-31 00:00:00,Tax Effect Of Unusual Items,
BALPHARMA.NS,income,2021-03-31 00:00:00,Tax Rate For Calcs,
BALPHARMA.NS,income,2021-03-31 00:00:00,Normalized EBITDA,
BALPHARMA.NS,income,2021-03-31 00:00:00,Total Unusual Items,
BALPHARMA.NS,income,2021-03-31 00:00:00,Total Unusual Items Excluding Goodwill,
BALPHARMA.NS,income,2021-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,
BALPHARMA.NS,income,2021-03-31 00:00:00,Reconciled Depreciation,
BALPHARMA.NS,income,2021-03-31 00:00:00,Reconciled Cost Of Revenue,
BALPHARMA.NS,income,2021-03-31 00:00:00,EBITDA,
BALPHARMA.NS,income,2021-03-31 00:00:00,EBIT,
BALPHARMA.NS,income,2021-03-31 00:00:00,Net Interest Income,
BALPHARMA.NS,income,2021-03-31 00:00:00,Interest Expense,
BALPHARMA.NS,income,2021-03-31 00:00:00,Interest Income,3142000.0
BALPHARMA.NS,income,2021-03-31 00:00:00,Normalized Income,
BALPHARMA.NS,income,2021-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,
BALPHARMA.NS,income,2021-03-31 00:00:00,Total Expenses,
BALPHARMA.NS,income,2021-03-31 00:00:00,Rent Expense Supplemental,6832000.0
BALPHARMA.NS,income,2021-03-31 00:00:00,Diluted Average Shares,
BALPHARMA.NS,income,2021-03-31 00:00:00,Basic Average Shares,
BALPHARMA.NS,income,2021-03-31 00:00:00,Diluted EPS,
BALPHARMA.NS,income,2021-03-31 00:00:00,Basic EPS,
BALPHARMA.NS,income,2021-03-31 00:00:00,Diluted NI Availto Com Stockholders,
BALPHARMA.NS,income,2021-03-31 00:00:00,Net Income Common Stockholders,
BALPHARMA.NS,income,2021-03-31 00:00:00,Otherunder Preferred Stock Dividend,
BALPHARMA.NS,income,2021-03-31 00:00:00,Net Income,
BALPHARMA.NS,income,2021-03-31 00:00:00,Minority Interests,
BALPHARMA.NS,income,2021-03-31 00:00:00,Net Income Including Noncontrolling Interests,
BALPHARMA.NS,income,2021-03-31 00:00:00,Net Income Continuous Operations,
BALPHARMA.NS,income,2021-03-31 00:00:00,Tax Provision,
BALPHARMA.NS,income,2021-03-31 00:00:00,Pretax Income,
BALPHARMA.NS,income,2021-03-31 00:00:00,Other Non Operating Income Expenses,
BALPHARMA.NS,income,2021-03-31 00:00:00,Special Income Charges,
BALPHARMA.NS,income,2021-03-31 00:00:00,Other Special Charges,543000.0
BALPHARMA.NS,income,2021-03-31 00:00:00,Write Off,0.0
BALPHARMA.NS,income,2021-03-31 00:00:00,Net Non Operating Interest Income Expense,
BALPHARMA.NS,income,2021-03-31 00:00:00,Total Other Finance Cost,16190000.0
BALPHARMA.NS,income,2021-03-31 00:00:00,Interest Expense Non Operating,
BALPHARMA.NS,income,2021-03-31 00:00:00,Interest Income Non Operating,3142000.0
BALPHARMA.NS,income,2021-03-31 00:00:00,Operating Income,
BALPHARMA.NS,income,2021-03-31 00:00:00,Operating Expense,
BALPHARMA.NS,income,2021-03-31 00:00:00,Other Operating Expenses,
BALPHARMA.NS,income,2021-03-31 00:00:00,Depreciation And Amortization In Income Statement,
BALPHARMA.NS,income,2021-03-31 00:00:00,Amortization,11881000.0
BALPHARMA.NS,income,2021-03-31 00:00:00,Depreciation Income Statement,
BALPHARMA.NS,income,2021-03-31 00:00:00,Research And Development,185000.0
BALPHARMA.NS,income,2021-03-31 00:00:00,Selling General And Administration,123945000.0
BALPHARMA.NS,income,2021-03-31 00:00:00,Selling And Marketing Expense,102690000.0
BALPHARMA.NS,income,2021-03-31 00:00:00,General And Administrative Expense,21255000.0
BALPHARMA.NS,income,2021-03-31 00:00:00,Rent And Landing Fees,6832000.0
BALPHARMA.NS,income,2021-03-31 00:00:00,Gross Profit,
BALPHARMA.NS,income,2021-03-31 00:00:00,Cost Of Revenue,
BALPHARMA.NS,income,2021-03-31 00:00:00,Total Revenue,
BALPHARMA.NS,income,2021-03-31 00:00:00,Operating Revenue,
